Vascepa (icosapent ethyl)

We can help with your prescription. Read the “Prescription Guide”.

You can access this medicine even if it’s not approved in your country. Learn how.

Price Frequently Asked Questions Details Patient stories Import guides

Vascepa (icosapent ethyl) is a prescription medicine used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of of cardiovascular events

SKU: N/A Category: Cardiology

What is Vascepa (icosapent ethyl) for?

Vascepa (icosapent ethyl) is an ethyl ester of eicosapentaenoic acid (EPA) indicated as an adjunct therapy for adult patients with:

elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease or, diabetes mellitus and two or more additional risk factors for cardiovascular disease as an adjunct to maximally tolerated statin therapy.
severe (≥ 500 mg/dL) hypertriglyceridemia as an adjunct to diet.

Where has Vascepa (icosapent ethyl) been approved?

Vascepa (icosapent ethyl) has been approved by:

Food and Drug Administration (FDA), USA:
- On July 27, 2012 to reduce triglyceride levels in adults with severe hypertriglyceridemia
- On December 13, 2019 to reduce cardiovascular risk
Health Canada on January 2, 2020 to reduce cardiovascular risk
European Medicines Agency (EMA) on January 29, 2021 under the brand name Vazkepa to reduce cardiovascular risk